HSV-1-based amplicon vectors: Design and applications

Gene Therapy

Volumn 12, Issue , 2005, Pages S154-S158

  Epstein, Alberto L ^a  

^a CENTRE DE GÉNÉTIQUE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

Amplicons; Gene transfer; HSV 1

Indexed keywords

ANTIOXIDANT; APOPTOSIS INHIBITOR; BRAIN DERIVED NEUROTROPHIC FACTOR; DNA; GENE PRODUCT; HEAT SHOCK PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NERVE GROWTH FACTOR; NEUROTROPHIN; PLASMID VECTOR; VIRUS VECTOR;

AMPLICON; BACTERIAL ARTIFICIAL CHROMOSOME; CELL NUCLEUS; CONFERENCE PAPER; COSMID; DEFECTIVE VIRUS; FUNCTIONAL GENOMICS; GENE TECHNOLOGY; GENE TRANSFER; GENETIC TRANSDUCTION; HERPES SIMPLEX VIRUS 1; HOST RANGE; HUMAN; MAMMAL CELL; NONHUMAN; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM;

BACTERIA (MICROORGANISMS); HUMAN HERPESVIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS; MAMMALIA;

EID: 27544490857     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302617     Document Type: Article

References (45)

1. Spaete RR, Frenkel N. The herpes simplex virus amplicon: a new eucaryotic defective-virus cloning-amplifying vector. Cell 1982; 30: 295-304.
2. Geller AI, Keyomarsi K, Bryan J, Pardee AB. An efficient deletion mutant packaging system for defective herpes simplex virus vectors; potential applications to human gene therapy and neuronal physiology. Proc Natl Acad Sci USA 1990; 87: 8950-8954.
3. Johnson PA et al. Cytotoxicity of a replication-defective mutant of herpes simplex virus type 1. J Virol 1992; 66: 2952-2965.
4. Fraefel C et al. Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells. J Virol 1996; 70: 7190-7197.
5. Saeki Y et al. Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosomes in Escherichia coli: Rescue of replication-competent virus progeny and packaging of amplicon vectors. Hum Gene Ther 1998; 9: 2787-2794.
6. Saeki Y et al. Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in bacterial artificial chromosome. Mol Ther 2001; 3: 591-601.
7. Zaupa C, Revol-Guyot V, Epstein AL. Improved packaging system for generation of high-level non-cytotoxic HSV-1 amplicon vectors using Cre-loxP site-specific recombination to delete the packaging signals of defective helper genomes. Hum Gene Ther 2003; 14: 1049-1063.
8. Logvinoff C, Epstein AL. Intracellular Cre-mediated deletion of the unique packaging signal carried by a herpes simplex virus type 1 recombinant and its relationship to the cleavage- packaging process. J Virol 2000; 74: 8402-8412.
9. Logvinoff C, Epstein AL. A novel approach for herpes simplex virus type 1 amplicon production, using the Cre-loxP recombination system to remove helper virus. Hum Gene Ther 2001; 12: 161-167.
10. Wade-Martins R et al. An infectious transfer and expression system for genomic DNA loci in human and mouse cells. Nat Biotech 2001; 19: 1067-1070.
11. Wade-Martins R, Saeki Y, Chiocca EA. Infectious delivery of a 135-kb LDLR genomic locus leads to regulated complementation of low-density lipoprotein receptor deficiency in human cells. Mol Ther 2003; 7: 604-612.
12. Inoue R et al. Infectious delivery of the 132 kb CDKN2Al CDKN2B genomic DNA region results in correctly spliced gene expression and growth suppression in glioma cells. Gene Therapy 2004; 11: 1195-1204.
13. Wang S, Voss J-MH. A hybrid herpesvirus infectious vector based on Epstein-Barr virus and herpes simplex virus type 1 for gene transfer into human cells in vitro and in vivo. J Virol 1996; 70: 8422-8430.
14. Kwong AD, Frenkel N. The herpes simplex virus amplicon. IV. Efficient expression of a chimeric chicken ovalbumin gene amplified within defective virus genomes. Virology 1985; 142: 421-425.
15. Geller AI, Breakefield XO. A defective HSV-1 vector expresses Escherichia coli beta-galactosidase in cultured peripheral neurons. Science 1988; 241: 1667-1669.
16. Tung C et al. Rapid production of interleukin-2-secreting tumor cells by herpes simplex virus-mediated gene transfer: implications for autologous vaccine production. Hum Gene Ther 1996; 18: 2217-2224.
17. During MJ, Naegele JR, O'Malley KL, Geller AI. Long-term behavioural recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase. Science 1994; 266: 1399-1403.
18. Rainov NG et al. A chimeric fusion protein of cytochrome CYP4B1 and green fluorescent protein for detection of pro-drug activating gene delivery and for gene therapy in malignant glioma. Adv Exp Med Biol 1998; 451: 393-403.
19. hah K, Tang Y, Breakefield XO, Weissleder R. Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo. Oncogene 2003; 22: 6865-6872.
20. Herrlinger U et al. Helper virus-free helper simplex virus type 1 amplicon vectors for granulocyte-macrophage colony-stimulating factor-enhanced vaccination therapy for experimental glioma. Hum Gene Ther 2000; 11: 1429-1438.
21. Federoff HJ, Geschwind MD, Geller AI, Kessler JA. Expression of nerve growth factor in vivo from a defective herpes simplex virus 1 vector prevents effects of axotomy on sympathetic ganglia. Proc Nat Acad Sci USA 1992; 89: 1636-1640.
22. Geschwind MD et al. Defective HSV-1 vector expressing BDNF in auditory ganglia elicits neurite outgrowth: model for treatment of neuron loss following cochlear degeneration. Hum Gene Ther 1996; 7: 173-180.
23. Linnik MD, Zahos P, Gescwind MD, Federoff HJ. Expression of bcl-from a defective herpes simplec virus-1 vector limits neuronal death in focal cerebral ischemia. Stroke 1995; 26: 1670-167
24. Lawrence MS, Ho DY, Steinberg GK, Sapolsky RM. Overexpression of Bcl-2 with herpes simplex virus vectors protects CNS neurons against neurological insults in vitro and in vivo. J Neurosci 1996; 16: 486-496.
25. Hoehn B et al. Overexpression of HSP72 after induction of experimental stroke protects neurons from ischemic damage. J Cereb Blood Flow Metab 2001; 21: 1303-1309.
26. Wang H et al. Over-expression of antioxidant enzymes protects cultured hippocampal and cortical neurons from necrotic insults. J Neurochem 2003; 87: 1527-1534.
27. Geller AI et al. An HSV-1 vector expressing tyrosine hydroxylase causes production and release of l-DOPA from cultured rat striatal cells. J Neurochem 1995; 64: 487-496.
28. Sun M et al. Correction of a rat model of Parkinson's disease by coepression of tyrosine hydroxylase and aromatic amino acid decarboxylase from a helper virus-free herpes simplex virus type 1 vector. Human Gene Ther 2003; 14: 415-424.
29. Brooks AI et al. Enhanced learning in mice parallels vector- mediated nerve growth factor expression in hippocampus. Hum Gene Ther 2000; 11: 2341-2352.
30. Neill JC et al. Enhanced auditory reversal learning by genetic activation of protein kinase C in small groups of rat hippocampal neurons. Brain Res Mol Brain Res 2001; 93: 127-136.
31. Adrover M et al. Hippocampal infection with HSV-1-derived vectors expressing a NMDAR1 antisense modifies behavior. Genes Brain Behav 2003; 2: 103-113.
32. Cheli VT et al. Gene transfer of NMDAR1 subunit sequences to the rat CNS using herpes simplex virus vectors interfered with habituation. Cell Mol Neurobiol 2002; 3: 303-314.
33. Wang Y et al. HSV-1 amplicon vectors are a highly efficient gene delivery system for skeletal muscle myoblasts and myotubes. Am J Physiol Cell Physiol 2000; 278: 619-626.
34. Wang Y et al. Herpes simplex virus type 1 amplicon vector- mediated gene transfer to muscle. Hum Gene Ther 2002; 13: 261-273.
35. Ferrera R et al. Efficient and non-toxic gene transfer to cardiomyocytes using novel generation amplicon vectors derived from HSV-1. JMCC 2004; 3: 219-223.
36. Muller L et al. Gene transfer into hepatocytes mediated by herpes simplex virus-Epstein-Barr virus hybrid amplicons. J Virol Methods 2005; 123: 65-72.
37. Willis RA et al. Dendritic cells transduced with HSV-1 amplicons expressing prostate-specific antigen generate antitumor immunity in mice. Hum Gene Ther 2001; 12: 1867-1879.
38. Savard N, Cosset F-L, Epstein AL. Use of defective HSV-1 vectors harbouring Gag, Pol and Env genes to induce the rescue of defective retroviral vectors. J Virol 1997; 71: 4111-4117.
39. Parrish E et al. Cell engineering for muscle gene therapy: extemporaneous production of retroviral vector packaging macrophages using defective herpes simplex virus type 1 vectors harbouring gag, pol, env genes. Cytotechnology 1999; 30: 173-180.
40. Sena-Esteves M et al. Single-step convesion of cells to retrovirus vector producers with herpes simplex virus-Epstein-Barr virus hybrid amplicons. J Virol 1999; 73: 10426-10439.
41. Hong Z et al. Enzymatic characterization of hepatitis C virus NS3l4A complexes expressed in mammalian cells by using the herpes simplex virus amplicon system. J Virol 1996; 70: 4261-4268.
42. Tsitoura R et al. Expression of hepatitis C virus envelope glycoproteins by herpes simplex virus-1 based amplicon vectors. J Gen Virol 2002; 83: 561-566.
43. Johnston KM et al. HSV-1lAAV hybrid amplicon vectors extend trransgene expression in human glioma cells. Hum Gene Ther 1997; 10: 359-370.
44. Hocknell PK et al. Expression of human immunodeficiency virus type1 gp120 from herpes simplex virus type 1-derived amplicons result in potent, specific, and durable cellular and humoral immune responses. J Virol 2002; 76: 5565-5580.
45. Samaniego LA, Neiderhiser L, DeLuca NA. Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins. J Virol 1998; 72: 3307-3320.